Intrafractional vaginal dilation in anal cancer patients undergoing pelvic radiotherapy (DILANA) – a prospective, randomized, 2-armed phase-II-trial | BMC Cancer | Full Text

Intrafractional vaginal dilation in anal cancer patients undergoing pelvic radiotherapy (DILANA) – a prospective, randomized, 2-armed phase-II-trial | BMC Cancer | Full Text

Intrafractional vaginal dilation in anal cancer patients undergoing pelvic radiotherapy (DILANA) – a prospective, randomized, 2-armed phase-II-trial

The incidence of anal cancer is rising in the last decades and more women are affected than men. The prognosis after chemoradiation is very good with complete remission rates of 80–90%. Thus, reducing therapy-...

Authors:Nathalie Arians, Matthias Häfner, Johannes Krisam, Kristin Lang, Antje Wark, Stefan A. Koerber, Adriane Hommertgen and Jürgen Debus

Citation:BMC Cancer 2020 20:52

Content type:Study protocol

Published on: 21 January 2020

• ViewFull Text
 
• ViewPDF